



ORIGINAL ARTICLE

Increased plasma levels of N-terminal pro-B-type natriuretic peptide as biomarker for the diagnosis of cardioembolic ischaemic stroke



J.A. García-Carmona^{a,*}, E. Conesa-García^a, D. Vidal-Mena^a, M. González-Morales^b, V. Ramos-Arenas^b, C. Sánchez-Vizcaíno-Buendía^{a,c}, J.J. Soria-Torrecillas^a, J.A. Pérez-Vicente^{a,d}, L. García-de-Guadiana-Romualdo^b

^a Department of Neurology, Santa Lucia University Hospital, Cartagena, Spain

^b Laboratory Medicine Department, Santa Lucia University Hospital, Cartagena, Spain

^c Unit of Neurovascular, Department of Neurology, Santa Lucia University Hospital, Cartagena, Spain

^d Head of Department of Neurology, Santa Lucia University Hospital, Cartagena, Spain

Received 6 March 2021; accepted 24 September 2021

Available online 10 January 2022

KEYWORDS

NT-proBNP;
Cardioembolic
ischaemic stroke;
Stroke mortality;
Biomarkers

Abstract

Background: Despite comprehensive study, the aetiology of stroke is not identified in 35% of cases.

Aims: We conducted a study to assess the diagnostic capacity of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the identification of ischaemic stroke of cardioembolic origin. The secondary purpose of the study was to evaluate the prognostic value of NT-proBNP for predicting 90-day all-cause mortality.

Methods: We designed a prospective observational study including patients hospitalised due to stroke between March 2019 and March 2020. Blood samples were collected on admission to the emergency department and serum NT-proBNP levels were determined. Statistical analysis was performed using a bivariate logistic regression model and receiver operating characteristic (ROC) and Kaplan–Meier curves. Statistical significance was established at $p < .05$.

Results: The study included 207 patients with first ischaemic stroke. Plasma NT-proBNP levels were significantly higher ($p < .001$) in the cardioembolic stroke group ($2069 \text{ pg/mL} \pm 488.5$). ROC curves showed that NT-proBNP $> 499 \text{ pg/mL}$ was the optimum value for diagnosing cardioembolic ischaemic stroke (sensitivity, 82%; specificity, 80%). Moreover, plasma NT-proBNP levels $> 499 \text{ pg/mL}$ were independently associated with cardioembolic stroke (OR: 9.881; $p = .001$). Finally, NT-proBNP $> 1500 \text{ pg/mL}$ was useful for predicting 90-day mortality (sensitivity, 70%; specificity, 93%).

* Corresponding author.

E-mail address: dr.jagarcacar@gmail.com (J.A. García-Carmona).

PALABRAS CLAVE

NT-proBNP;
Ictus isquémico
cardioembólico;
Mortalidad del ictus;
Biomarcadores

Conclusions: NT-proBNP was independently associated with cardioembolic stroke and should be quantified in blood tests within 24 h of stroke onset. High plasma levels (>499 pg/mL) may indicate an underlying cardioembolic cause, which should be further studied, while NT-proBNP >1500 pg/mL was associated with increased 90-day mortality.

© 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Aumento de los niveles plasmáticos del péptido natriurético N-terminal pro-B (NT-proBNP) como biomarcador para el diagnóstico del ictus isquémico cardioembólico

Resumen

Introducción: A pesar de un completo y exhaustivo estudio, la etiología de un 35% de los ictus isquémicos es desconocida.

Objetivos: Evaluar la capacidad de diagnóstico del NT-proBNP en la identificación del ictus isquémico de origen cardioembólico. El objetivo secundario fue evaluar el valor pronóstico del NT-proBNP como predictor de mortalidad de cualquier causa tras 90 días del ictus.

Métodos: Diseñamos un estudio observacional prospectivo, incluyendo pacientes hospitalizados por ictus. El periodo de reclutamiento fue de marzo de 2019 a marzo de 2020. Se obtuvieron muestras de sangre a su admisión en Urgencias y se midieron los niveles plasmáticos de NT-proBNP. El análisis estadístico fue realizado mediante un modelo bivariado de regresión logística, curva de la característica operativa del receptor (curvas ROC) y curvas Kaplan-Meier. Se consideraron significativas diferencias con $p < 0,05$.

Resultados: Fueron incluidos 207 pacientes con un primer episodio de ictus isquémico agudo. Los niveles de NT-proBNP fueron significativamente mayores ($p < 0,001$) en el grupo de ictus isquémico cardioembólico ($2.069 \pm 488,5$). Las curvas ROC mostraron que un NT-proBNP > 499 pg/mL es el valor óptimo para el diagnóstico de ictus isquémico cardioembólico (sensibilidad 82%, especificidad 80%). Además, los niveles plasmáticos de NT-proBNP > 499 pg/mL estaban asociados de forma independiente con el ictus isquémico cardioembólico (OR = 9.881, $p = 0,001$). Finalmente, un valor de NT-proBNP > 1.500 pg/mL fue útil para predecir la mortalidad de cualquier causa 90 días tras el ictus isquémico (sensibilidad = 70%, especificidad = 93%).

Conclusiones: El valor de NT-proBNP estaba asociado independientemente al ictus isquémico de origen cardioembólico y debería ser considerado su análisis en las primeras 24 h desde el inicio del ictus. Niveles elevados (NT-proBNP > 499 pg/mL) pueden indicar un origen cardioembólico subyacente, el cual debería ser estudiado con mayor detalle, mientras que niveles de NT-proBNP > 1.500 pg/mL se asociaron con un incremento de la mortalidad a los 90 días del ictus.

© 2021 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Stroke is the most frequent cause of permanent disability in adulthood and one of the leading causes of death in Spain and worldwide.^{1,2} In particular, the incidence of stroke is 187/100,000 inhabitants in Spain.^{3,4}

The diagnosis of stroke is more difficult in the first hours, mainly if the onset is unknown, the signs are atypical, the patient is agitated and access to the image is delayed. Etiologically, ischaemic stroke is classified according to different classification systems such as the TOAST classification⁵ the ASCOD phenotyping system⁶ and the Causal System classification.⁷ All of them recognize the existence of ischaemic stroke of cardioembolic origin. Cardioembolic stroke has been associated with highest

in-hospital mortality during the acute phase of stroke, higher rates of disability, neurological impairment, recurrence and worse prognosis.⁸ For these reasons, its diagnosis is of great importance for adequate treatment and correct secondary prevention. Despite a complete and exhaustive study, the origin of 35% of strokes is undetermined.⁹ In many of these cases, as well as in strokes of cardioembolic origin, the presence of a paroxysmal atrial fibrillation (AF) arrhythmia is the triggering cause of the episode.¹⁰ In this regard; cardiac blood biomarkers represent an objective measurement of molecular characteristics which may help in the diagnosis.

The N-terminal pro-type-B natriuretic peptide (NT-proBNP) is the proBNP's inactive residue released from the heart's left ventricle in response to wall stress

through volume expansion and increased pressure.¹¹ Its levels increase with heart failure, myocardial infarctions, atrial fibrillation and are higher in women and elderly.¹² In the last few years, NT-proBNP emerged as a serum biomarker in stroke. A recent meta-analysis with data from 2834 patients demonstrated that natriuretic peptides are strongly increased in cardioembolic strokes.¹³ Nonetheless, a cut-off value was not obtained. Only few small studies showed different NT-proBNP cut-off values (>200 pg/mL, >265.5 pg/mL and >313 pg/mL) to be associated with cardioembolic stroke.^{14–16} Furthermore, natriuretic peptides have been found to correlate with stroke severity and mortality.¹⁷

Therefore, the primary aim of the present study was to assess the diagnostic ability of NT-proBNP for the identification of ischaemic stroke of cardioembolic origin. The secondary purpose was to evaluate the prognostic value of NT-proBNP for predicting 90-days all-cause mortality.

Methods

Study design and clinical protocol

This is a prospective observational study including adult patients hospitalized by stroke at the Santa Lucia University Hospital from Cartagena, Spain; and designed following the STARD guidelines.¹⁸ The recruitment period was from March 1, 2019 to March 1, 2020. All adult patients (≥ 18 years) with clinically suspected stroke in Emergency Department were eligible for the study. Exclusion criteria were: presence of (a) solid tumours or lymphomas; (b) chronic and acute heart failure; (c) haemorrhagic stroke; (d) brain bleeding secondary to amyloid congophil angiopathy, aneurysms, subarachnoid haemorrhage; (e) concomitant infections; (f) other complications such as epileptic seizures or acute myocardial infarction and (g) lack of analytical/clinical data.

Stroke diagnosis was performed by trained neurologists according to the World Health Organization definition¹⁹ and confirmed by neuroimaging. Symptoms severity was assessed by using the National Institutes of Health²⁰ and the following variables related to the stroke were collected: systolic and diastolic blood pressure, glucose, LDL-cholesterol and creatinine. Stroke acute treatment and its secondary prevention treatment were carried out by neurologists following approved clinical guidelines^{21–24} but not any specific treatment or intervention for this study. Patients' medical history was reviewed and collected the following covariates: high blood pressure, diabetes, dyslipidemia, atrial fibrillation, cardiac valvulopathy or shunt, chronic kidney disease, previous stroke, tobacco and alcohol consume, anticoagulants and antiplatelets intake.

Blood sampling and laboratory methods

Blood samples were collected by venipuncture into tubes with separator gel (BD Vacutainer SST II Advance 8.5 mL) within the first 24 h of admission. Tubes were immediately centrifuged (3500 rpm for 10 min at room temperature) and

separated serum was used for the immediate measurement of NT-proBNP, the results of which were not reported to the attending physicians.

Serum NT-proBNP levels were measured on a Cobas e702 analyzer (Roche Diagnostics, Mannheim, Germany) by an electrochemiluminescence immunoassay (ECLIA). According to manufacturer's data, detection limit, functional sensitivity and measurement range were 10 pg/mL, 50 pg/mL and 10–35,000 pg/mL, respectively.

Statistical analysis

Continuous variables were tested for normal distribution using the Kolmogorov–Smirnov's test. Data are summarized as numbers and frequencies for categorical variables and medians with interquartile ranges (IQRs) for continuous data. Comparisons between groups were performed with Chi-squared test for categorical data and Mann–Whitney *U* and Kruskal–Wallis for continuous data.

For the first purpose, discriminatory ability of NT-proBNP for cardioembolic stroke was evaluated by calculating the area under the receiver operating characteristic curve (AUC-ROC) and we additionally calculated the optimal ROC-derived cutoff value according to Youden Index. Binary logistic regression was performed to identify variables associated with cardioembolic stroke. To achieve the best set of predictors, only variables with a statistical trend in univariate analysis ($p < 0.10$) were selected for multivariate analysis. Covariates were retained in the final model if they were statistical significant with a p -value of < 0.05 .

For the second purpose, ROC analysis with calculation of the AUC was performed to evaluate the utility of NT-proBNP for prognosis of all-cause mortality in all patients after 90 days. We identified independent predictors for 90-day mortality by Cox regression analysis and Kaplan–Meier survival curves, according to NT-proBNP quartiles, were constructed for comparison among survivors and non-survivors.

We performed analyses by using the software packages SPSS 21.0 (SPSS Inc., IL, USA) and MedCalc 15.0 (MedCalc Software, Ostend, Belgium). In all tests, a two-sided p -value of < 0.05 was considered significant.

Results

In the study period, 207 consecutive patients with a suspected stroke at the time of first medical evaluation were recruited. After exclusion criteria were applied, 156 patients (72 women, 84 men; mean age: 69.3 ± 0.9) were finally included, as showed in the study's protocol flowchart (Fig. 1).

Baseline characteristics are shown in Table 1. Patients diagnosed with cardioembolic stroke were significantly older (75.2 ± 1.9 ; $p = 0.010$) and associated higher rates of atrial fibrillation/shunt or cardiac valvulopathy (76%; $p = 0.001$) and oral anticoagulants intake (44%; $p = 0.001$) versus other stroke groups. In contrast, the prevalence of smokers were significantly lower in the cardioembolic group (7%; $p = 0.026$). Finally, plasma LDL-cholesterol values were significantly higher (132.5 ± 7.7 ; $p = 0.008$) in the large-vessel




Figure 1 Study's flowchart.

Table 1 Patients' history and stroke related clinical parameters.

	Total N = 156	UND N = 39	SVo N = 52	LAA N = 38	CE N = 27	p-value
Age (y ± SEM)	69.3 ± 0.9	68.9 ± 2.1	65.8 ± 1.6	68.5 ± 1.9	75.2 ± 1.9	0.010
Sex (%)						0.189
Women	72 (46)	20 (51)	26 (50)	12 (32)	14 (52)	
Men	84 (54)	19 (49)	26 (50)	26 (68)	13 (48)	
Patient's history (%)						
HBP	115 (67)	29 (74)	31 (60)	24 (63)	20 (74)	0.296
DM	51 (30)	13 (33)	22 (42)	9 (24)	2 (7)	0.016
DLP	82 (48)	20 (52)	28 (54)	16 (42)	10 (37)	0.360
AF/valve/shunt	50 (14)	12 (31)	10 (19)	3 (8)	21 (76)	0.001
Stroke	32 (19)	7 (18)	10 (19)	6 (16)	7 (26)	0.780
CKD	12 (7)	3 (8)	2 (4)	2 (5)	1 (4)	0.849
Tobacco	49 (29)	10 (26)	18 (35)	13 (34)	2 (7)	0.026
Alcohol	33 (19)	9 (23)	10 (19)	10 (26)	1 (4)	0.123
OACs	23 (14)	4 (10)	4 (8)	1 (3)	12 (44)	0.001
Antiplatelets	34 (20)	9 (23)	12 (23)	6 (16)	4 (15)	0.707
Stroke parameters (±SEM)						
SBP	142.6 ± 1.7	139.1 ± 4.1	137.1 ± 2.6	142.5 ± 3.1	141.5 ± 3.8	0.629
DBP	80.7 ± 1.0	80.1 ± 2.3	78.6 ± 1.7	79.8 ± 1.7	79.2 ± 2.9	0.953
Glu	128.6 ± 3.7	130.6 ± 7.5	128.9 ± 7.1	129.2 ± 9.4	114.4 ± 5.3	0.537
LDL	114.7 ± 6.8	100.0 ± 7.1	117.8 ± 6.3	132.5 ± 7.7	103.5 ± 6.9	0.008
Cr	1.54 ± 0.6	3.64 ± 2.6	0.85 ± 0.3	0.89 ± 0.4	1.01 ± 0.7	0.357
NT-proBNP	640.6 ± 107.5	596.9 ± 139.3	185.2 ± 28.7	293.6 ± 86.4	2069.2 ± 488.5	0.001
NIHSS score	5.53 ± 0.5	6.7 ± 1.0	2.5 ± 0.5	5.2 ± 0.9	7.6 ± 1.4	0.001

Abv: UND = undetermined; SVo = small vessel disease; LAA = large artery atherothrombosis; CE = cardioembolic; y = years; HBP = high blood pressure; DM = diabetes mellitus; DLP = dyslipidemia; AF = atrial fibrillation; CKD = chronic kidney disease; OACs = oral anticoagulants; SBP = systolic blood pressure; DBP = diastolic blood pressure; Glu = glucose; LDL = low density lipoprotein; Cr = creatinin; NT-proBNP = N-terminal-pro brain derived natriuretic Peptide; NIHSS = national institute health stroke scale.

stroke group and the NIHSS score were significantly lower in the small vessel group (2.5 ± 0.5 ; $p < 0.001$).

NT-proBNP in ischaemic stroke sub-types

We compared the plasma levels of NT-proBNP in each group of stroke by TOAST classification: small vessel disease stroke (SVo), large artery atherothrombosis stroke (LAA), cardioembolic stroke (CE) and stroke of undetermined cause (UND). As shown in Fig. 2, Kruskal–Wallis revealed a significant increased NT-proBNP plasma levels in the cardioembolic stroke group (2069 ± 488.5) versus the large vessel (293.6 ± 86.35 ; $***p = 0.0001$), small vessel (185.2 ± 28.66 ; $***p = 0.0001$) and undetermined (596.9 ± 139.3 ; $##p = 0.0088$) stroke groups.

NT-proBNP cut-off value

In supplementary material (A) is shown the area under the receiver operating characteristics curve (ROC) of NT-proBNP for diagnosis of cardioembolic stroke which was 0.853 (CI95% = 0.766–0.941; $p < 0.001$). As shown in Table 2, Youden index indicated that the optimal cut-off value of NT-proBNP was 499 pg/mL (sensitivity 82%, specificity 80%).

NT-proBNP and cardioembolic stroke

A logistic bivariate regression analysis was used to truly establish the parameters independently associated with cardioembolic stroke. As shown in Table 3, bivariate logistic regression analysis showed that NT-proBNP plasma levels were independently associated to cardioembolic stroke (OR = 1.01, CI95% = 1.00–1.02, $p < 0.003$). Furthermore, bivariate logistic regression analysis showed that NT-proBNP > 499 pg/mL were independently associated to cardioembolic stroke (OR = 9.881, CI95% = 2.831–34.489, $p = 0.001$).

Cardioembolic stroke, NT-proBNP and mortality

We examined the survival at 90 days in both, cardioembolic and no-cardioembolic stroke (Fig. 3A). Log rank (Mantel–Cox) showed no statistical differences ($p = 0.495$) between cardioembolic ($n = 3$; 17.15%, CI95% = 9.35–24.6) and no-cardioembolic ($n = 9$; 15.49%, CI95% = 11.95–19.02) stroke in death, by all causes, at 90 days. Furthermore, we first obtained a NT-proBNP > 1500 pg/mL cut-off value (COR curve: AUC = 0.885, CI95% = 0.81–0.96%; $p = 0.001$; sensitivity = 70%, specificity = 93%) to predict mortality at 90 days post-stroke (see supplementary material). Secondly we examined the prognostic value of a NT-proBNP > 1500 pg/mL. Kaplan–Meier analysis (Fig. 3B) revealed that NT-proBNP > 1500 pg/mL were found to significantly ($p = 0.001$) increase the mortality at 90 days (38.0%, CI95% = 32.2–53.8) after stroke versus lower plasma levels (12.5%, CI95% = 10.19–14.93). In this regard, 8 of 12 deaths were in patients with NT-proBNP > 1500 pg/mL. In this subgroup of patients, 7 deaths were directly attributed to stroke severity and 1 was caused by traumatic car accident. The causes of death in the 4 patients with

NT-proBNP < 1500 pg/mL were (all after hospital discharge): 2 sepsis, 1 heart attack and 1 intestinal haemorrhage in a patient anticoagulated by femoral artery occlusion.

Discussion

NT-proBNP cut-off value

Our results showed that NT-proBNP > 499 pg/mL was useful to predict cardioembolic stroke (sensitivity 82%, specificity 80%). In the last few years, different studies assessed an optimal cut-off value for discriminating the presence of a cardioembolic source. For example, Zecca et al.¹⁴ showed a level of NT-proBNP > 200 pg/mL and calculated a 65% sensitivity and 82% specificity 0.82 while Hajsadeghi et al.²⁵ showed a cut-off value > 342 pg/mL (93% sensitivity, 73% specificity). A recent study showed that NT-proBNP ≥ 505 pg/mL distinguished AF-related from non-cardiac stroke with a sensitivity of 93% and a specificity of 72%.²⁶ Interestingly, cut-off value of NT-proBNP has been shown not only within 24 h of stroke but also 7 and 90 days after (NT-proBNP > 313; > 181 and > 174 pg/mL, respectively).¹⁶ Future research and meta-analysis are needed to establish a common, accurate and reliable NT-proBNP's cut-off value.

NT-proBNP and cardioembolic stroke

Our results demonstrated that NT-proBNP plasma levels were higher and independently associated to cardioembolic stroke. A large-scale European prospective study showed that levels of NT-proBNP are positively associated with ischaemic stroke, independently from several other risk factors.²⁷ In this line, a prospective study using the ARIC cohort demonstrated an association between NT-proBNP plasma levels and cardioembolic stroke but not with lacunar or haemorrhagic stroke.²⁸ Furthermore, a recent prospective study showed that patients with cardioembolic stroke had higher NT-proBNP.²⁶ Finally, a recent meta-analysis showed that both, BNP and NT-proBNP display closely equivalent diagnostic accuracies in distinguishing cardioembolic ischaemic stroke from non-cardioembolic, with NT-proBNP showing a superior specificity.²⁹ Altogether, these results suggest that NT-proBNP could be a useful biomarker of cardioembolic stroke and therefore may help clinicians to select patients for further etiologic study with subcutaneous Holter monitor. Further research is needed to rule out the impact of NT-proBNP in the etiologic study in patients with undetermined cause of stroke.

Stroke aetiology, NT-proBNP and mortality

Our results demonstrated no differences in mortality within stroke sub-types while a NT-proBNP > 1500 pg/mL showed increased mortality after 90 days post-stroke. Mortality of ischaemic stroke has been widely studied in long-term. Nonetheless, short-term mortality has been scarcely studied and is about 8% after 30 days.³⁰ According to previous studies³¹ we found no differences in mortality between




Figure 2 N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels by ischaemic stroke sub-type. Data are expressed as the mean $\pm$ SEM. Kruskal–Wallis test: *** $p < 0.001$ vs. SVo and LAA; ## vs. UND stroke. Abv: SVo = small vessel occlusion stroke ($n = 52$); LAA = large artery atherosclerosis stroke ($n = 38$); CE = cardioembolic stroke ($n = 27$); UND = undetermined aetiology stroke ($n = 39$); NT-proBNP = N-terminal pro-brain natriuretic peptide.

Table 2 Best cut-off points to differentiate cardioembolic ischaemic stroke.

	NT-proBNP cut-off points		
	Value (pg/mL)	Sensitivity (%)	Specificity (%)
Best sensitivity	39.5	100	8.45
More sensitive	293	85	70
Optimum value	499	82	80
Best specificity	4797.5	11.1	100

Table 3 Non-cardioembolic vs. cardioembolic stroke by bivariate logistic regression model.

	OR	IC95%	p-Value
Age	0.999	0.949–1.055	0.986
DM	4.550	0.870–23.683	0.072
AF/valve/shunt	0.395	0.126–1.237	0.111
Tobacco	5.866	0.598–57.575	0.129
LDL	0.998	0.985–1.011	0.768
NT-proBNP	1.001	1.000–1.002	0.003
NT-proBNP >499	9.881	2.831–34.489	0.001

Abv: DM = diabetes mellitus; AF = atrial fibrillation; LDL = low density lipoprotein; NT-proBNP = N-terminal-pro brain derived natriuretic peptide.

cardioembolic and no-cardioembolic stroke, by all causes, up-to 90 days. Nonetheless, that study showed an increased mortality in cardioembolic stroke group after 1 and 5 years. Moreover, Bjerkreima et al.³² showed cardioembolic stroke had a 34% higher risk of death within 5 years while small vessel occlusion had a 48% lower risk of death. In this regard, the risk of recurrent stroke is increased in cardioembolic stroke and, as previously shown; stroke recurrence may be associated with increased in-hospital mortality.³³

Altogether, our data support previous findings indicating no differences in short-term mortality between subtypes of ischaemic stroke. In addition, recent evidence suggests that plasma levels of natriuretic peptides might be related

to mortality after stroke. In particular, high BNP levels (>500 pmol/L) have been shown to be an independent prognostic value for mortality after stroke.³⁴ A meta-analysis showed that high NT-proBNP plasma levels (>1453 pg/mL) were independently associated to mortality post-stroke with no differences between stroke sub-type. Furthermore, this study demonstrated that NT-proBNP had an added value (discrete) respect to simple clinical variables in ranking patients at high risk of death after stroke.¹⁷ As suggested by Jickling and Foerch³⁵ the ability of NT-proBNP to predict mortality after stroke may relate to disease other than stroke. As previously showed, NT-proBNP is an independent predictor of mortality in cardiac dysfunction, in kidney




Figure 3 Kaplan–Meier survival curves at 90 days. (A) Kaplan–Meier curves comparing survival between cardioembolic and non-cardioembolic stroke groups. (B) Kaplan–Meier curves comparing survival of patients with a NT-proBNP > 1500 pg/mL. The *p* values were obtained from the log rank tests. Abv: CE = cardioembolic stroke, NT-proBNP = N-terminal pro-brain natriuretic peptide.

disease,³⁶ diabetes³⁷ and cardiac surgery.³⁸ Nonetheless, a NT-proBNP > 1500 pg/mL value could be useful for clinicians to inform patients' family about a poor prognosis at 90 days. Further research is needed to assess the specific management and better treatment in that group of patients with worse prognosis after stroke.

Conclusions

In summary, our results demonstrated that NT-proBNP > 499 pg/mL plasma levels may indicate an underlying cardiac cause which should be further studied. Furthermore, despite cardioembolic ischaemic stroke being not associated with higher mortality after 90 days; NT-proBNP > 1500 pg/mL plasma levels are associated with increased mortality. Therefore, NT-proBNP should be considered for blood testing within 24 h of stroke.

Limits

This study has several limitations that must be pointed out. First, we excluded patients with conditions which are able to enhance NT-proBNP plasma levels such as sepsis, malignant tumours, chronic or acute heart failure and haemorrhagic stroke. We excluded haemorrhagic stroke patients because a CT scan is mandatory in the diagnosis of acute stroke and then, the differential diagnosis between ischaemic and haemorrhagic stroke is done. For the same reason, we found low mortality rates; therefore the results for mortality prediction should be interpreted with caution.

Secondly, although the NT-proBNP value is measured upon arrival at the hospital, the time from the onset of the stroke to the arrival of the patient is variable due to various causes such as the distance to the hospital or the underestimation of the symptoms by the patient or even an incorrect initial

diagnosis. Nonetheless, hospital admission is an easily reproducible clinical time point, increasing the external validity of our study and facilitating the replication of our results in clinical practice.

Contributorship

ECG, DVM, VRA, MGM and JAGC collected data. JAGC, JAPV, LGGR, JJST, CSVB researched literature and designed the study. JAGC, LGGR were involved in protocol development, gaining ethical approval and data analysis. JAGC and LGGR wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Ethical approval

The study was performed according to the Declaration of Helsinki and approved by the Research Ethic Committee of the Murcia Health Service (E.O. 2020-37 BNPCS2020-01). No identifiable information was retained or is presented in this manuscript.

Informed consent

Informed consent was not required for the present study because no additional blood tests were needed as recognized by the Ethical Committee.

Guarantor

Not applicable.

Funding

The authors neither received public or private funding nor grant to carry out this study.

Conflict of interests

The Authors declare that there is no conflict of interest.

Acknowledgements

Not reported.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.nrl.2021.09.014](https://doi.org/10.1016/j.nrl.2021.09.014).

References

- Soriano JB, Rojas-Rueda D, Alonso J, Antó JM, Cardona PJ, Fernández E, et al. La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. *Med Clin*. 2018;151:171–90, <http://dx.doi.org/10.1016/j.medcli.2018.05.011>.
- Krishnamurthi RV, Moran AE, Feigin VL, Barker-Collo S, Norrving B, Mensah GA, et al. Stroke prevalence mortality and disability-adjusted life years in adults aged 20–64 years in 1990–2013: data from the global burden of disease 2013 study. *Neuroepidemiology*. 2015;45:190–202, <http://dx.doi.org/10.1159/000441098>.
- Marrugat J, Arboix A, García-Eroles L, Salas T, Vila J, Castell C, et al. The estimated incidence and case fatality rate of ischemic and hemorrhagic cerebrovascular disease in 2002 in Catalonia. *Revista Española de Cardiología*. 2007;60:575–80.
- Díaz-Guzmán J, Egido JA, Gabriel-Sánchez R, Barberá-Comes G, Fuentes-Gimeno B, Fernández-Pérez C. Stroke and Transient ischemic attack incidence rate in Spain: the IBERICTUS study. *Cerebrovasc Dis*. 2012;34:272–81.
- Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke*. 1993;24:35–41.
- Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). *Cerebrovasc Dis*. 2013;36:1–5.
- Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. *Stroke*. 2007;38:2979–84.
- Arboix A, Alió J. Acute cardioembolic stroke: an update. *Expert Rev Cardiovasc Ther*. 2011;9:367–79, <http://dx.doi.org/10.1586/erc.10.192>.
- Weimar C. Stroke of undetermined cause: workup and secondary prevention. *Curr Opin Neurol*. 2016;29:4–8, <http://dx.doi.org/10.1097/WCO.0000000000000280>.
- Haeusler KG, Tütüncü S, Schnabel RB. Detection of atrial fibrillation in cryptogenic stroke. *Curr Neurol Neurosci Rep*. 2018;18:66, <http://dx.doi.org/10.1007/s11910-018-0871-1>.
- Magnussen C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. *J Int Med*. 2018;283:530–43.
- Cauliez B, Merthe MC, Lavoine A. Brain natriuretic peptide: physiological, biological and clinical aspects. *Ann Biol Clin (Paris)*. 2005;63:15–25.
- Llombart V, Antolin-Fontes A, Bustamante A, Giralt D, Rost N, Furie K, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis pooled data meta-analysis. *Stroke*. 2015;46:1187–95, <http://dx.doi.org/10.1161/STROKEAHA.114.008311>.
- Zecca B, Mandelli C, Maino A, Casiraghi C, Bolla G, Consonni D, et al. A bioclinical pattern for the early diagnosis of cardioembolic stroke. *Emerg Med Int*. 2014:132–41.
- Fonseca AC, Matias JS, Pinho e Melo T, Falcão F, Canhão P, Ferro JM. N-terminal probrain peptide as a biomarker of cardioembolic stroke. *Int J Stroke*. 2011;6:398–403, <http://dx.doi.org/10.1111/j.1747-4949.2011.00606.x>.
- Purroy F, Suárez-Luis I, Mauri-Capdevila G, Cambray S, Farré J, Sanahuja J, et al. N-terminal pro-brain natriuretic peptide level determined at different times identifies transient ischaemic attack patients with atrial fibrillation. *Eur J Neurol*. 2014;21:679–83, <http://dx.doi.org/10.1111/ene.12222>.
- García-Berrocó TD, Giralt A, Bustamante T, Etgen JK, Jensen JC, Sharma K, et al. B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. *Neurology*. 2013;81:1976–85, <http://dx.doi.org/10.1212/01.wnl.0000436937.32410.32>.
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015 an updated list of essential items for reporting diagnostic accuracy studies. *BMJ*. 2015;351:h5527, <http://dx.doi.org/10.1136/bmj.h5527>.
- Campbell BC, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, et al. Ischaemic stroke. *Nat Rev Dis Primers*. 2019;5:70, <http://dx.doi.org/10.1038/s41572-019-0118-8>.
- Montaner J, Alvarez-Sabin J. NIH stroke scale and its adaptation to Spanish. *Neurología*. 2006;21:192–202.
- García Pastor A, López-Cancio Martínez E, Rodríguez-Yañez M, Alonso de Leciñana M, Amaro S, Arenillas JF, et al. Recommendations of the Spanish Society of Neurology for the prevention of stroke Interventions on lifestyle and air pollution. *Neurología*. 2021;76:377–87, <http://dx.doi.org/10.1016/j.nrl.2020.05.018>.
- Rodríguez-Yañez M, Gómez-Choco M, López-Cancio E, Amaro S, Alonso de Leciñana S, Arenillas JF, et al. Stroke prevention in patients with arterial hypertension: recommendations of the Spanish Society of Neurology's Stroke Study Group. *Neurología*. 2021;36:462–71.
- Palacio-Portilla EJ, Roquer J, Amaro S, Arenillas JF, Ayo-Martín O, Castellanos M, et al. Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. *Neurología*. 2020, <http://dx.doi.org/10.1016/j.nrl.2020.07.027> [in press].
- Fuentes B, Amaro S, Alonso de Leciñana M, Arenillas JF, Ayo-Martín O, Castellanos M, et al. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology. *Neurología*. 2021;36:305–23, <http://dx.doi.org/10.1016/j.nrl.2020.04.030>.
- Hajsaideghi S, Amin LK, Bakhshandeh H, Rohani M, Azizian AR, Kerman SJ. The diagnostic value of N-terminal pro-brain natriuretic peptide in differentiating cardioembolic ischemic stroke. *J Stroke Cerebrovasc Dis*. 2013;22:554–60.
- Kneihl M, Gattringer T, Bisping E, Scherr D, Raggam R, Mangge H, et al. Blood biomarkers of heart

- failure and hypercoagulation to identify atrial fibrillation-related stroke. *Stroke*. 2019;50:2223–6, <http://dx.doi.org/10.1161/STROKEAHA.119.025339>.
27. Di Castelnuovo A, Veronesi G, Costanzo S, Zeller T, Schnabel RB, Curtis A, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide) and the risk of stroke. *Stroke*. 2019;50:610–7, <http://dx.doi.org/10.1161/STROKEAHA.118.023218>.
 28. Folsom AR, Nambi V, Bell E, Oluleye O, Gottesman R, Lutsey P, et al. N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. *Stroke*. 2013;44:961–7, <http://dx.doi.org/10.1161/STROKEAHA.111.000173>.
 29. Bai J, Sun H, Xie L, Zhu Y, Feng Y. Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal proBNP: a comparative diagnostic meta-analysis. *Int J Neurosci*. 2018;128:1100–8, <http://dx.doi.org/10.1080/00207454.2017.1408612>.
 30. Koton S, Tanne D, Green MS, Bornstein NM. Mortality and predictors of death 1 month and 3 years after first-ever ischemic stroke: data from the first national acute stroke Israeli survey (NASIS 2004). *Neuroepidemiology*. 2010;34:90–6, <http://dx.doi.org/10.1159/000264826>.
 31. Rücker V, Heuschmann PU, O'Flaherty M, Weingärtner M, Hess M, Sedlak C, et al. Twenty-year time trends in long-term case-fatality and recurrence rates after ischemic stroke stratified by etiology. *Stroke*. 2020;51:2778–85, <http://dx.doi.org/10.1161/STROKEAHA.120.029972>.
 32. Bjerkreima AT, Khanevskib AN, Thomassena L, Selvika HA, Waje-Andreassen U, Naessa H, et al. Five-year readmission and mortality differ by ischemic stroke subtype. *J Neurol Sci*. 2019;403:31–7.
 33. Arboix A, García-Eroles L, Massons J, Oliveres M. Predictive clinical factors of in-hospital mortality in 231 consecutive patients with cardioembolic cerebral infarction. *Cerebrovasc Dis*. 1998;8:8–13.
 34. Mäkilä AM, Mäkilä TH, Korpelainen JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, et al. Natriuretic peptides and mortality after stroke. *Stroke*. 2005;36:1016–20, <http://dx.doi.org/10.1161/01.STR.0000162751.54349.ae>.
 35. Jickling GC, Christian Foerch C. Predicting stroke mortality: BNP could it be? *Neurology*. 2013;81:1970–1, <http://dx.doi.org/10.1212/01.wnl.0000436949.75473.79>.
 36. Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Christensen JH. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. *Clin Nephrol*. 2009;71:380–6.
 37. Bhalla MA, Chiang A, Epshteyn VA, Kazanegra R, Bhalla V, Clifton P, et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. *J Am Coll Cardiol*. 2004;44:1047–52.
 38. Hutfless R, Kazanegra R, Madani M, Bhalla MA, Tulua-Tata A, Chen A, et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. *J Am Coll Cardiol*. 2004;43:1873–9.